Professional Traders

[PoemStone]

Big Board Bios (Friday).

StocksDiva
http://investorshub.advfn.com/StocksDiva-Bio-Bin-16112/

Oculus Innovative Sciences, Inc. (Nasdaq: OCLS), announced it has enrolled the first patients in its double-blind, randomized clinical study evaluating an advanced Microcyn® hydrogel for management of hypertrophic or keloid scars under an FDA-reviewed protocol.

The company plans to complete its 40-patient trial and provide top-line data by mid-2013 calendar year. The study design calls for recruitment of up to 40 patients at four different U.S. sites, which are Albuquerque, NM, High Point, NC, Austin, TX and College Station, TX.

DARA BioSciences, Inc. (Nasdaq: DARA) announced it has entered into an exclusive distribution agreement with Seyer Pharmatec Inc. for the sale and distribution of Soltamox (tamoxifen citrate, oral solution) in the Commonwealth of Puerto Rico. DARA plans to launch Soltamox later this year.

After a competitive multi-state process, Accelr8 Technology Corporation (NYSE MKT: AXK) today announces that it is moving its headquarters from Denver, CO to Tucson, AZ.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, today reported preliminary results from Phase 1 studies of LX2931 and LX7101.


Oncolytics Biotech Inc. (TSX:ONC, NASDAQ: ONCY) today announced that it has completed patient enrollment in its U.S. Phase I clinical trial using REOLYSIN in combination with FOLFIRI (Folinic Acid (leucovorin) with Fluorouracil (5-FU) and Irinotecan) in patients with oxaliplatin refractory, Kras mutant colorectal cancer (REO 022).

Oncolytics Biotech Inc. (TSX:ONC) (NASDAQ: ONCY) today announced that it has completed patient enrollment in its U.K. Phase I clinical trial using intravenously-administered REOLYSIN in combination with cyclophosphamide in patients with advanced malignancies (REO 012).

Perrigo Company (Nasdaq: PRGO; TASE) today announced results for its fourth quarter and full year ended June 30, 2012.

WuXi PharmaTech (NYSE: WX) today announced that its toxicology facility in Suzhou had received a Certificate of Good Laboratory Practice (GLP) from the State Food and Drug Administration (SFDA) of the People's Republic of China after successfully passing two GLP inspections conducted by the SFDA.